Monograph
Losartan — The Uricosuric ARB with a Marfan and TGF-β Story
Losartan (Cozaar, first FDA-approved 1995) is the prototype angiotensin II receptor blocker. It shares the class-level mechanism (selective AT1 receptor blockade), core indications (hypertension, diabetic nephropathy, heart failure, cardiovascular…
By Kristopher Crawford
·
05 July 2026
·
11 min read
Losartan (Cozaar, first FDA-approved 1995) is the prototype angiotensin II receptor blocker. It shares the class-level mechanism (selective AT1 receptor blockade), core indications (hypertension, diabetic nephropathy, heart failure, cardiovascular…
In the full monograph
- What it is, and how it works
- What the evidence shows — randomized trials, observational data, animal studies, graded and cited
- Dose, form, and timing
- What to expect, and how soon
- Who should be careful, and what to check first
- The verdict
MEMBERS
Read the full monograph
Members get every monograph in the library, the research assistant, and the stack tracker — with a 30-day money-back guarantee. Not ready? Start free with the Proven Supplements Starter Guide.